Journal
BRITISH JOURNAL OF CANCER
Volume 104, Issue 2, Pages 361-368Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605971
Keywords
heterogeneity; cervical cancer; chemoradiotherapy; array CGH; selection
Categories
Funding
- Cancer Research UK
- University of Cambridge
- Hutchison Whampoa Ltd
- Cambridge Experimental Cancer Medicine Centre
- NIHR Biomedical Research Centre
- Royal College of Radiologists
- Cancer Research UK [15601] Funding Source: researchfish
Ask authors/readers for more resources
BACKGROUND: Intra-tumour genetic heterogeneity has been reported in both leukaemias and solid tumours and is implicated in the development of drug resistance in CML and AML. The role of genetic heterogeneity in drug response in solid tumours is unknown. METHODS: To investigate intra-tumour genetic heterogeneity and chemoradiation response in advanced cervical cancer, we analysed 10 cases treated on the CTCR-CE01 clinical study. Core biopsies for molecular profiling were taken from four quadrants of the cervix pre-treatment, and weeks 2 and 5 of treatment. Biopsies were scored for cellularity and profiled using Agilent 180k human whole genome CGH arrays. We compared genomic profiles from 69 cores from 10 patients to test for genetic heterogeneity and treatment effects at weeks 0, 2 and 5 of treatment. RESULTS: Three patients had two or more distinct genetic subpopulations pre-treatment. Subpopulations within each tumour showed differential responses to chemoradiotherapy. In two cases, there was selection for a single intrinsically resistant subpopulation that persisted at detectable levels after 5 weeks of chemoradiotherapy. Phylogenetic analysis reconstructed the order in which genomic rearrangements occurred in the carcinogenesis of these tumours and confirmed gain of 3q and loss of 11q as early events in cervical cancer progression. CONCLUSION: Selection effects from chemoradiotherapy cause dynamic changes in genetic subpopulations in advanced cervical cancers, which may explain disease persistence and subsequent relapse. Significant genetic heterogeneity in advanced cervical cancers may therefore be predictive of poor outcome. British Journal of Cancer (2011) 104, 361-368. doi: 10.1038/sj.bjc.6605971 www.bjcancer.com Published online 9 November 2010 (C) 2011 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available